NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 13 August 2025

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice Chair) Present for all items
3. Andrew Fox Present for all items
4. Dr Bernard Khoo Present for items 1 to 4.2.2
5. Professor David Meads Present for all items
6. Giles Monnickendam Present for items 5.1 to 6.2.2
7. Dr Guy Makin Present for all items
8. Martin Bradley Present for all items
9. Dr Miranda Trevor Present for all items
10. Paul Caulfield Present for all items
11. Dr Philip Mallender Present for all items
12. Dr Robert Hodgson Present for all items
13. Dr Salman Waqar Present for items 1 to 6.2.1
14. Samuel Finnikin Present for all items
15. Dr Savvas Vlachos Present for items 1 to 6.2.1
16. Professor Sofia Dias Present for all items
17. Dr Zenas Yiu Present for items 1 to 5.2.2

NICE staff (key players) present

Christian Griffiths, Principal Technical Adviser Items 4.1 to 4.2.2

Kate Moore, Project Manager Items 4.1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Adviser Items 4.1 to 4.2.2

Sammy Shaw, Heath Technology Assessment Analyst Items 4.1 to 4.2.2

Adam Brooke, Principal Technical Adviser Items 5.1 to 5.2.2

Jeremy Powell, Project Manager Items 5.1 to 5.2.2

Sam Slayen, Heath Technology Assessment Adviser Items 5.1 to 6.2.2

George Millington, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Ian Watson, Associate Director Items 6.1 to 6.2.2

Jen Upton, Project Manager Items 6.1 to 6.2.2

Emma Bajela, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Willem Witlox, Kleijnen Systematic Reviews Ltd Items 4.1 to 4.1.3

Huiqin Yang, Kleijnen Systematic Reviews Ltd Items 4.1 to 4.1.3, 6.1 to 6.1.3

Sarah Davis, Sheffield Centre for Health and Related Research (SCHARR) Items 5.1 to 5.1.3

Sarah Ren, Sheffield Centre for Health and Related Research (SCHARR) Items 5.1 to 5.1.3

Bram Rameakers, Kleijnen Systematic Reviews Ltd Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Lewis Brimble, Trustee of MPGN/DDD Support Group, patient expert nominated by MPGN/DDD Support Group Items 4.1 to 4.1.3

Professor David Kavanagh, Professor of Complement Therapeutics, clinical expert nominated by Novartis Items 4.1 to 4.1.3

Professor Matthew Pickering, Professor of Rheumatology, clinical expert nominated by MPGN/DDD Support Group Items 4.1 to 4.1.3

Prof Sanjay Popat, Consultant Thoracic Medical Oncologist, clinical expert nominated by Janssen-Cilag Ltd (for item 5) and British Thoracic Oncology Group (for item 6) Items 5.1 to 5.1.3, 6.1 to 6.1.3

Dr Adam P Januszewski, Consultant Medical Oncologist, clinical expert nominated by the British Thoracic Oncology Group Items 5.1 to 5.1.3

Professor Gini Harrison, patient expert nominated by EFGR+ Items 5.1 to 5.1.3, 6.1 to 6.1.3

James Richardson, National Specialty Advisor (Cancer Drugs), CDF lead Items 5.1 to 5.1.3, 6.1 to 6.1.3

Dr Spyros Gennetas, Consultant Medical Oncologist, clinical expert nominated by AstraZeneca Items 6.1 to 6.1.3

Sophie McCluskey, patient expert nominated by EGFR+ UK Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Dr Ben Searle, Carole Pitkeathley, Catherine Thompson, Nathan Moore, Sophia Steer, Sue Wen Leo, and Will Sullivan.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 9th July 2025.

### Appraisal of Iptacopan for treating complement 3 glomerulopathy [ID6283]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11331).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Bernard Khoo, Paul Caulfield and Prof. Sofia Dias.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11331) in due course.

### Appraisal of Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

* 1. Part 1 – Open session
     1. The vice-chair, Dr Raju Reddy, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Johnson & Johnson Innovative Medicine.
     2. The vice-chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11279).
     3. The vice-chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the vice-chair.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11279) in due course.

### Appraisal of Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

* 1. Part 1 – Open session
     1. The vice-chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Johnson & Johnson Innovative Medicine.
     2. The vice-chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11023).
     3. The vice-chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the vice-chair.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting.
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11023) in due course.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 10th September 2025 and will start promptly at 9am.